当前位置: 首页 >> 检索结果
共有 4689 条符合本次的查询结果, 用时 6.3021541 秒

561. Xunming Ji: preventing and treating stroke in China.

作者: Tony Kirby.
来源: Lancet. 2025年

562. Percutaneous transcatheter valve replacement in individuals with mitral regurgitation unsuitable for surgery or transcatheter edge-to-edge repair: a prospective, multicountry, single-arm trial.

作者: Mayra E Guerrero.;David V Daniels.;Raj R Makkar.;Vinod H Thourani.;Federico M Asch.;Michael Pham.;Kamran I Muhammad.;Adam B Greenbaum.;Alejandro Vasquez.;J Bradley Oldemeyer.;Thom G Dahle.;Charanjit Rihal.;M Andrew Morse.;Evelio Rodriguez.;Brian P O'Neill.;Mark Russo.;Brian Whisenant.;Pradeep Yadav.;Xiao Yu.;Dee Dee Wang.;Moody Makar.;David A Baran.;Paul Mahoney.;Gautam Reddy.;Philipp Blanke.;John Webb.; .
来源: Lancet. 2025年406卷10519期2541-2550页
Patients with severe mitral regurgitation are frequently not candidates for surgery or transcatheter edge-to-edge repair (TEER). We aimed to evaluate 1-year outcomes of a novel percutaneous transseptal transcatheter mitral valve replacement (TMVR) system in patients unsuitable for surgery or TEER.

565. Drug-coated balloon angioplasty and stenting for coronary artery lesions - Authors' reply.

作者: Chao Gao.;Yoshinobu Onuma.;Patrick W Serruys.;Ling Tao.
来源: Lancet. 2025年406卷10514期1951-1952页

566. Drug-coated balloon angioplasty and stenting for coronary artery lesions.

作者: Tuomas T Rissanen.;Simon Eccleshall.;Raban Jeger.;Azeem Latib.;Bruno Scheller.
来源: Lancet. 2025年406卷10514期1950-1951页

567. Drug-coated balloon angioplasty and stenting for coronary artery lesions.

作者: Filippo Luca Gurgoglione.;Bernardo Cortese.
来源: Lancet. 2025年406卷10514期1950页

568. Drug-coated balloon angioplasty and stenting for coronary artery lesions.

作者: Christian Spaulding.;Simon Eccleshall.;Florian Krackhardt.;Philip Urban.
来源: Lancet. 2025年406卷10514期1949-1950页

569. Drug-coated balloon angioplasty and stenting for coronary artery lesions.

作者: Pitt O Lim.
来源: Lancet. 2025年406卷10514期1949页

570. Drug-coated balloon angioplasty and stenting for coronary artery lesions.

作者: Tingquan Zhou.
来源: Lancet. 2025年406卷10514期1948-1949页

571. Rethinking atherosclerotic disease prevention.

作者: Valery L Feigin.;Sheila O Martins.;Graeme J Hankey.
来源: Lancet. 2025年406卷10514期1947页

572. Integrating preconception health into CVD prevention.

作者: Chahinda Ghossein-Doha.;Sevda Ece Kizilkilic.;Paul Dendale.
来源: Lancet. 2025年406卷10514期1947-1948页

573. Plant-based diets for coronary artery disease prevention.

作者: Joshua J Hon.;Jimmy K F Hon.
来源: Lancet. 2025年406卷10514期1946-1947页

574. Loans dominated COVID-19 funding: it's time to adjust.

作者: Jehane Sedky.;Abbey Gardner.;Louise C Ivers.
来源: Lancet. 2025年406卷10514期1946页

575. Cinematic portrayals of euthanasia and ageing across the decades.

作者: Neasa Fitzpatrick.;Desmond O'Neill.
来源: Lancet. 2025年406卷10514期1942-1943页

576. Offline: "People have died".

作者: Richard Horton.
来源: Lancet. 2025年406卷10514期1934页

577. Optimising treatment strategies in older patients with mantle cell lymphoma.

作者: Eva Giné.;Amanda Isabel Perez-Valencia.
来源: Lancet. 2025年406卷10514期1924-1925页

578. Drug pricing and pharmaceutical innovation: a false promise.

作者: The Lancet.
来源: Lancet. 2025年406卷10514期1923页

579. Lessons from CONCORD and VENUSCANCER: closing global gaps in cancer care for women.

作者: Benjamin O Anderson.;Catherine Duggan.
来源: Lancet. 2025年406卷10517期2298-2300页

580. Non-coeliac gluten sensitivity.

作者: Jessica R Biesiekierski.;Daisy Jonkers.;Carolina Ciacci.;Imran Aziz.
来源: Lancet. 2025年406卷10518期2494-2508页
Non-coeliac gluten sensitivity (NCGS) refers to individuals who report intestinal and extraintestinal symptoms related to the ingestion of gluten-based or wheat-based foods, in the absence of coeliac disease or wheat allergy. Gluten is found in multiple cereals, including wheat, rye, and barley, although the precise trigger of symptoms in NCGS remains unclear. Although approximately 10% of adults worldwide self-report gluten or wheat sensitivity, meta-analyses suggest that, during controlled challenge studies, 16-30% of these individuals have symptoms specifically triggered by gluten. However, methodological variability-including the presence of fermentable carbohydrates in challenge preparations-limits interpretation. Current evidence suggests that fermentable carbohydrates and nocebo effects contribute considerably to symptom generation in many cases. The substantial size of the gluten-free market raises questions about commercial and media influences on how NCGS is portrayed, and on the direction of related research. Definitive diagnosis of NCGS remains elusive due to the absence of biomarkers, significant overlap with disorders of gut-brain interaction, and methodological challenges in dietary evaluation. Until causative agents are identified and diagnostic tests developed, NCGS remains a diagnosis of exclusion, requiring careful systematic evaluation. Management approaches should balance dietary modification with recognition of psychological factors while ensuring nutritional adequacy. This Review critically examines current evidence regarding NCGS as a distinct entity, explores potential mechanisms, and provides practical guidance for assessment and management, while acknowledging major uncertainties in the field.
共有 4689 条符合本次的查询结果, 用时 6.3021541 秒